Outcome of the Board Meeting held on Wednesday, November 12, 2025 pursuant to Regulations 30, 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and 0.8 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Prevest Denpro's Board approved unaudited standalone and consolidated financial results for Q2 FY26 and the six months ended September 30, 2025. Standalone revenue from operations grew to ₹1,866.30 lakhs (up ~14.8% YoY from ₹1,625.67 lakhs), while net profit rose to ₹556.95 lakhs (up ~15.1% YoY) with EPS at ₹4.64. For the H1 FY26 period, standalone net profit came in at ₹1,020.38 lakhs (up ~20.2% YoY) on revenue of ₹3,438.57 lakhs. Profitability margins expanded meaningfully, with standalone EBITDA margin improving to roughly 45% in H1 FY26 from ~42% in H1 FY25, driven by better cost control. The statutory auditor (Mittal & Associates) issued a clean limited review report with no qualifications or adverse remarks. Cash generation remained strong with standalone operating cash flow of ₹700.49 lakhs and cash & equivalents climbing to ₹6,705.44 lakhs.
A clean auditor report, double-digit growth in revenue and profits, expanding margins, and a robust cash pile should be viewed positively by shareholders and could support stock price momentum. No red flags on governance, debt, or auditor continuity.